X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.500
+0.170 (5.11%)
Mar 4, 2026, 4:00 PM EST - Market closed
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 143 employees as of December 31, 2024. The number of employees increased by 50 or 53.76% compared to the previous year.
Employees
143
Change (1Y)
50
Growth (1Y)
53.76%
Revenue / Employee
$237,615
Profits / Employee
-$665,000
Market Cap
306.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 143 | 50 | 53.76% |
| Dec 31, 2023 | 93 | 23 | 32.86% |
| Dec 31, 2022 | 70 | -13 | -15.66% |
| Dec 31, 2021 | 83 | 11 | 15.28% |
| Dec 31, 2020 | 72 | 14 | 24.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Puma Biotechnology | 172 |
| AC Immune | 172 |
| Nautilus Biotechnology | 124 |
| Adlai Nortye | 123 |
| Enlivex | 71 |
| ALX Oncology Holdings | 44 |
| Fennec Pharmaceuticals | 32 |
XFOR News
- 1 day ago - X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - GlobeNewsWire
- 1 day ago - X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha
- 2 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome - GlobeNewsWire
- 16 days ago - X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 4 weeks ago - X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia - Seeking Alpha
- 4 months ago - X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference - GlobeNewsWire